PT - JOURNAL ARTICLE AU - Jon Sussman AU - Maria E Farrugia AU - Paul Maddison AU - Marguerite Hill AU - M Isabel Leite AU - David Hilton-Jones TI - Myasthenia gravis: Association of British Neurologists’ management guidelines AID - 10.1136/practneurol-2015-001126 DP - 2015 Jun 01 TA - Practical Neurology PG - 199--206 VI - 15 IP - 3 4099 - http://pn.bmj.com/content/15/3/199.short 4100 - http://pn.bmj.com/content/15/3/199.full SO - Pract Neurol2015 Jun 01; 15 AB - Myasthenia gravis is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence based medicine. The basic principles of treatment are well known, however, patients continue to receive suboptimal treatment as a result of which a myasthenia gravis guidelines group was established under the aegis of The Association of British Neurologists. These guidelines attempt to steer a path between evidence-based practice where available, and established best practice where evidence is unavailable. Where there is insufficient evidence or a choice of options, the guidelines invite the clinician to seek the opinion of a myasthenia expert. The guidelines support clinicians not just in using the right treatments in the right order, but in optimising the use of well-known therapeutic agents. Clinical practice can be audited against these guidelines.